. 2024 Jun 17;38:100318. doi: 10.1016/j.scog.2024.100318

Table 3.

Main and interaction effects.

	Effects	Group F(1,41)	Trial Type F(4,164)	Condition F(1,41)	Group ∗ Trial Type F(4,164)	Group ∗ Condition F(1,41)	Trial Type ∗ Condition F(4,164)	Group ∗ Trial Type ∗ Condition F(4,164)
ANOVA	PET	4.79; p = .03; η² = 0.11	9.17; p < .001; η² = 0.18	14.54; p = .00; η² = 0.26	1.29; p = .27	0.386; p = .54	7.12; p = .00; η² = 0.15	3.13; p = .02; η² = 0.07
	T1	5.57; p = .02; η² = 0.12	9.17; p < .001; η² = 0.19	8.05; p = .01; η² = 0.16	2.86; p = .03; η² = 0.07	0.038; p = .85	2.55; p = .04; η² = 0.06	0.22; p = .93
	T2	5.59; p = .02; η² = 0.12	7.27; p = .010; η² = 0.15	5.59; p = .02; η² = 0.12	1.37; p = .25	0.60; p = .44	2.72; p = .03; η² = 0.06	0.24; p = .92
	POT	18.69; p = .00; η² = 0.31	10.01; p = .00; η² = 0.20	10.01; p = .00; η² = 0.20	1.89; p = .11	4.75; p = .04; η² = 0.10	5.10; p = .01; η² = 0.11	0.99; p = .42

	Effects	Group F(1,37)	Trial Type F(4,148)	Condition F(1,37)	Group ∗ Trial Type F(4,148)	Group ∗ Condition F(1,37)	Trial Type ∗ Condition F(4,148)	Group ∗ Trial Type ∗ Condition F(4,148)
ANCOVA	PET	1.52; p = .23	0.06; p = .99	16.00; p = .00; η² = 0.30	0.60; p = .66	0.08; p = .79	5.84; p = .00; η² = 0.14	2.48; p = .05; η² = 0.06
	T1	0.99; p = .33	0.57; p = .69	6.09; p = .02; η² = 0.14	1.37; p = .25	0.37; p = .55	2.29; p = .06	0.24; p = .92
	T2	1.08; p = .31	0.34; p = .85	5.45; p = .03; η² = 0.13	1.15; p = .34	0.16; p = .69	2.32; p = .06	0.18; p = .95
	POT	4.52; p = .04; η² = 0.11	0.25; p = .91	7.15; p = .01; η² = 0.16	1.16; p = .33	2.90; p = .10	4.76; p = .01; η² = 0.11	1.88; p = .12